Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K L Franson

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Nederlands Tijdschrift Voor Geneeskunde|February 21, 2004
[Integration of training in pharmacology and pharmacotherapy in the medical curriculum in Leiden, the Netherlands]E A Dubois, K L Franson, J M van Gerven, et al.
Journal of Psychopharmacology (Oxford, England)|July 23, 2003
REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteersB Rijnbeek, S J de Visser, K L Franson, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2008
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteersS L de Haas, K L Franson, J A J Schmitt, et al.
Drugs & Aging|July 1, 1995
Drug-induced seizures in the elderly. Causative agents and optimal managementK L Franson, D P Hay, V Neppe, et al.
Journal of Psychopharmacology (Oxford, England)|August 4, 2009
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjectsM Liem-Moolenaar, R W M Zoethout, P de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|February 10, 2010
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjectsM Liem-Moolenaar, R W M Zoethout, P de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|August 30, 2008
Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidolM Liem-Moolenaar, F A Gray, S J de Visser, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Nederlands Tijdschrift Voor Geneeskunde|February 21, 2004
[Integration of training in pharmacology and pharmacotherapy in the medical curriculum in Leiden, the Netherlands]E A Dubois, K L Franson, J M van Gerven, et al.
Journal of Psychopharmacology (Oxford, England)|July 23, 2003
REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteersB Rijnbeek, S J de Visser, K L Franson, et al.
Journal of Psychopharmacology (Oxford, England)|July 19, 2008
The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteersS L de Haas, K L Franson, J A J Schmitt, et al.
Drugs & Aging|July 1, 1995
Drug-induced seizures in the elderly. Causative agents and optimal managementK L Franson, D P Hay, V Neppe, et al.
Journal of Psychopharmacology (Oxford, England)|August 4, 2009
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjectsM Liem-Moolenaar, R W M Zoethout, P de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|February 10, 2010
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjectsM Liem-Moolenaar, R W M Zoethout, P de Boer, et al.
Journal of Psychopharmacology (Oxford, England)|August 30, 2008
Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidolM Liem-Moolenaar, F A Gray, S J de Visser, et al.
Pageof 2